As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of vTv Therapeutics Inc. The largest reported stake is Samsara BioCapital, L.P.'s, at 9.9%. 10 filings are on record since September 3, 2025 (Schedule 13D/A, December 9, 2025).
Sell to companies like vTv Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Integrated Core Strategies (US) LLC · Sole voting: 0 · Shared voting: 312,138 · Sole dispositive: 0 · Shared dispositive: 312,138 · SCHEDULE 13G/A, 2026-10-08
- · Holder: Millennium Management LLC · Percent: 6.9% · SCHEDULE 13G/A
- · Holder: Millennium Management LLC · Percent: 5.7% · SCHEDULE 13G/A
- · Holder: Millennium Management LLC · Percent: 5% · SCHEDULE 13G
- · Holder: Samsara BioCapital, L.P. · Percent: 9.9% · SCHEDULE 13D/A
vTv Therapeutics Inc. has 10 Schedule 13D or 13G filings on record since 2025-09-03. 4 holders' latest filing reports 5% or more of class a common stock, par value $0.01 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Samsara BioCapital, L.P. | 9.9% | 246,484 | SCHEDULE 13D/A, 2025-12-09 | 2025-12-08 |
| Trails Edge Capital Partners, LP | 9.9% | 340,536 | SCHEDULE 13G, 2025-09-08 | 2025-08-29 |
| 9.4% | 393,098 | SCHEDULE 13G/A, 2025-11-12 | 2025-09-30 | |
| Millennium Management LLC | 8.7% | 342,481 | SCHEDULE 13G/A, 2026-10-08 | 2026-09-30 |
Holding shares or following this stake? See who's behind vTv Therapeutics Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on vTv Therapeutics Inc. and the records around it.
vTv Therapeutics Inc. elsewhere on the record
Companies that share a holder
- Samsara BioCapital, L.P. also filed stake reports on 14 other companies: PMV Pharmaceuticals, Inc. (Sep 2026), Eloxx Pharmaceuticals, Inc. (Aug 2026), RANI THERAPEUTICS HOLDINGS, INC. (May 2026)
- Trails Edge Capital Partners, LP also filed stake reports on 16 other companies: Avalo Therapeutics, Inc. (Oct 2026), Sol-Gel Technologies Ltd. (Oct 2026), Contineum Therapeutics, Inc. (Oct 2026)
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
Watch vTv Therapeutics Inc.
Get an email when vTv Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on vTv Therapeutics Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on vTv Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on vTv Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Integrated Core Strategies (US) LLC | 0 | 312,138 | 0 | 312,138 | SCHEDULE 13G/A, 2026-10-08 |
| Millennium Management LLC | 0 | 342,481 | 0 | 342,481 | SCHEDULE 13G/A, 2026-10-08 |
| Millennium Group Management LLC | 0 | 342,481 | 0 | 342,481 | SCHEDULE 13G/A, 2026-10-08 |
| Israel A. Englander | 0 | 342,481 | 0 | 342,481 | SCHEDULE 13G/A, 2026-10-08 |
The latest filing identifies vTv Therapeutics Inc. by CUSIP 918385204 and gives its principal executive office as 3980 Premier Drive, Suite 110, High Point, NC 27265 (SCHEDULE 13G/A, 2026-10-08).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-03 | Samsara BioCapital, L.P. | 9.9% | SCHEDULE 13D/A |
| 2025-09-08 | Trails Edge Capital Partners, LP | 9.9% | SCHEDULE 13G |
| 2025-09-08 | Raymond Debbane | 9.99% | SCHEDULE 13G |
| 2025-09-25 | Samsara BioCapital, L.P. | 9.9% | SCHEDULE 13D/A |
| 2025-11-12 | Raymond Debbane | 9.4% | SCHEDULE 13G/A |
| 2025-12-09 | Samsara BioCapital, L.P. | 9.9% | SCHEDULE 13D/A |
| 2026-03-27 | Millennium Management LLC | 5% | SCHEDULE 13G |
| 2026-04-16 | Millennium Management LLC | 5.7% | SCHEDULE 13G/A |
| 2026-07-29 | Millennium Management LLC | 6.9% | SCHEDULE 13G/A |
| 2026-10-08 | Millennium Management LLC | 8.7% | SCHEDULE 13G/A |
Questions about who owns vTv Therapeutics Inc.
Who owns vTv Therapeutics Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of vTv Therapeutics Inc.: Samsara BioCapital, L.P. (9.9%, Schedule 13D/A, filed 2025-12-09), Trails Edge Capital Partners, LP (9.9%, Schedule 13G, filed 2025-09-08), Raymond Debbane (9.4%, Schedule 13G/A, filed 2025-11-12) and Millennium Management LLC (8.7%, Schedule 13G/A, filed 2026-10-08).
Who are the largest shareholders of vTv Therapeutics Inc.?
By the share each holder's latest filing reports, the largest holders of vTv Therapeutics Inc. on this page are Samsara BioCapital, L.P. (9.9%), Trails Edge Capital Partners, LP (9.9%) and Raymond Debbane (9.4%).
When did Samsara BioCapital, L.P. buy into vTv Therapeutics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Samsara BioCapital, L.P. on this page is the Schedule 13D/A, filed 2025-09-03, reporting 9.9%; its latest, Schedule 13D/A filed 2025-12-09, reports 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for vTv Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.